Logo
x

Search

Subscribe Now

abbVie

AbbVie Join Forces with EvolveImmune Therapeutics for Developing Next-Generation Biotherapeutics in Oncology

AbbVie Join Forces with EvolveImmune Therapeutics for Developing Next-Generation Biotherapeutics in Oncology

  • November 4, 2024
AbbVie Inks Pact with Gedeon Richter to Discover and Develop Novel Targets for Neuropsychiatric Conditions

AbbVie Inks Pact with Gedeon Richter to Discover and Develop Novel Targets for Neuropsychiatric Conditions

  • October 25, 2024
AbbVie Reports the US FDA’s Approval of Botox Cosmetic (OnabotulinumtoxinA) for Moderate to Severe Vertical Bands Connecting the Jaw and Neck

AbbVie Reports the US FDA’s Approval of Botox Cosmetic (OnabotulinumtoxinA) for Moderate to Severe Vertical Bands Connecting the J...

  • October 21, 2024
AbbVie Reports the US FDA’s Approval of Vyalev (Foscarbidopa and Foslevodopa) for Treating Advanced Parkinson's Disease

AbbVie Reports the US FDA’s Approval of Vyalev (Foscarbidopa and Foslevodopa) for Treating Advanced Parkinson's Disease

  • October 18, 2024
AbbVie Seeks the US FDA’s Accelerated Approval of Telisotuzumab Vedotin (Teliso-V) for Treating Non-Squamous NSCLC

AbbVie Seeks the US FDA’s Accelerated Approval of Telisotuzumab Vedotin (Teliso-V) for Treating Non-Squamous NSCLC

  • September 30, 2024
AbbVie Reports Topline Data from P-III (TEMPO-1) Study of Tavapadon Alone for Parkinson's Disease

AbbVie Reports Topline Data from P-III (TEMPO-1) Study of Tavapadon Alone for Parkinson's Disease

  • September 27, 2024
Image

Incisive News in 3 Shots.

Contact Us

Our Information

Follow Us

Copyright © 2024 PharmaShots - All Rights Reserved.